Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study
| Autor: | Daudén, E, Griffiths, Cem, Ortonne, J-P, Kragballe, K, Molta, Ct, Robertson, D, Pedersen, R, Estojak, J, Boggs, R |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Zdroj: | Daudén, E, Griffiths, C, Ortonne, J-P, Kragballe, K, Molta, C, Robertson, D, Pedersen, R, Estojak, J & Boggs, R 2009, ' Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study ', Journal of the European Academy of Dermatology and Venereology . https://doi.org/10.1111/j.1468-3083.2009.03321.x |
| DOI: | 10.1111/j.1468-3083.2009.03321.x |
| Popis: | Udgivelsesdato: 2009-Jun-26 Objective To assess patient-reported outcomes (PRO) in patients with moderate-to-severe plaque psoriasis receiving continuous or paused etanercept treatment. Methods In a multicentre European open-label study, one group (n = 352) received continuous therapy: 25 mg subcutaneously (SC) twice weekly (BIW) throughout 54-weeks. The other group (n = 359) received paused therapy: 50 mg SC BIW ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|